Search Our Scientific Publications & Authors

Radiother Oncol 2020 Sep 11;154:255-259. Epub 2020 Sep 11.

Dept. Radiation Oncology, University Hospital Ulm, Germany. Electronic address:

Background: In prostate cancer (PCa) recurring after radical prostatectomy (RP), salvage radiotherapy (SRT) is recommended to be given at PSA <0.5 ng/ml. It has been speculated, that the advantage from early SRT is mainly caused by lead-time bias: Calculating from time of SRT, earlier treatment would per-se result in longer time to event/censoring compared with later treatment, but not extend the interval from RP to post-SRT failure. Read More

JAMA Oncol 2020 05;6(5):735-743

Department of Radiation Oncology, University of Michigan, Ann Arbor.

Importance: In men with recurrent prostate cancer, addition of long-term antiandrogen therapy to salvage radiotherapy (SRT) was associated with overall survival (OS) in the NRG/RTOG 9601 study. However, hormone therapy has associated morbidity, and there are no validated predictive biomarkers to identify which patients derive most benefit from treatment.

Objective: To examine the role of pre-SRT prostate-specific antigen (PSA) levels to personalize hormone therapy use with SRT. Read More

Int J Radiat Oncol Biol Phys 2020 06 25;107(2):288-296. Epub 2020 Jan 25.

Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom; Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom. Electronic address:

Purpose: Although high-level evidence supports moderately hypofractionated radiation therapy for definitive prostate treatment, there is less evidence for its use in the postprostatectomy setting. We externally validated a contemporary nomogram predicting biochemical failure (BF) after salvage radiation therapy (SRT) and report long-term disease control outcomes for hypofractionated SRT to the prostate bed.

Methods And Materials: A retrospective review was performed for 112 patients treated with hypofractionated SRT (52. Read More

Clin Genitourin Cancer 2019 10 24;17(5):e930-e938. Epub 2019 May 24.

Cedars-Sinai Medical Center, Los Angeles, CA.

Purpose: In order to better time salvage radiotherapy (SRT) for post-radical prostatectomy biochemical failure, we examined the association between pre-SRT prostate-specific antigen (PSA) and PSA control as a function of the new prognostic grade group (PGG) system.

Patients And Methods: Using the Shared Equal Access Regional Cancer Hospital database, we identified men after radical prostatectomy with PSA > 0.2 ng/mL and without cancer involvement of lymph nodes who underwent SRT alone. Read More

BJU Int 2019 11 6;124(5):785-791. Epub 2019 Jul 6.

Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.

Objective: To test whether salvage radiotherapy (SRT) in patients with lymph node negative (N0) prostate cancer is equally effective with persistent prostate-specific antigen (PSA) and PSA rising from the undetectable range (<0.1 ng/mL) after radical prostatectomy (RP).

Patients And Methods: We assessed post-SRT PSA progression-free survival (PFS) in 555 patients with prostate cancer. Read More